CIPLA's weekly performance was disappointing, with a return of -3.42% and a max drawdown of the same magnitude, indicating a significant decline in value. The stock's volatility was moderate at 11.2%, but its Sharpe ratio of -1.63 suggests that the return was not justified by the level of risk taken. Compared to its peers, CIPLA underperformed SUNPHARMA and DIVISLAB, but outperformed GRASIM. Overall, the stock was relatively risky this week.

[Volatility: 11.2%]